Mid Cap · Healthcare · Biotechnology
Mid Cap · Healthcare · Biotechnology
Get the AI take on IOVA
Track it to unlock the price chart, verdict and what could change it.
Free to track. No card required.
Overall score
N/A/100
See the full financial picture
Open the five-year record, valuation checks and Wall Street view behind these scores.
Free for 3 days, then $9/mo. Cancel anytime.
Lowest
$4
Current price
$8.3
Median target
$9
Highest
$14
Forward P/E
No signal · Not enough data to judge
-
Price / sales
Rich · Priced well above what its revenue alone supports
9.80x
Price / FCF
No signal · Not enough data to judge
-
EV / EBITDA
No signal · Not enough data to judge
-
ROIC
Weak · Struggling to earn much on the capital it uses
-24.1%
ROE
Weak · Weak returns on shareholders' money
-40.4%
Debt / equity
Strong · Very little debt relative to equity
0.06x
Current ratio
Strong · Comfortable room to cover bills due within a year
4.35x
| Company | Mkt cap | P/E | Rev growth | Score |
|---|---|---|---|---|
| $3.21B | - | +34.5% | - | |
| $11.53B | 22.0 | +19.7% | 78 | |
| $4.60B | 13.9 | +13.5% | 77 | |
| $33.87B | 35.4 | +15.5% | 77 | |
| $1.11T | 40.1 | +49.6% | 76 |